HistoIndex Collaborates with A*STAR to Enhance Early-Stage Therapy Development for Fibrosis
HistoIndex Partners with ASTAR to Tackle Fibrotic Diseases
In a significant move to boost early-stage therapeutic developments for fibrotic diseases, HistoIndex, a trailblazer in AI-driven digital pathology, has joined forces with the Agency for Science, Technology and Research (ASTAR) of Singapore. The partnership was formalized through a Memorandum of Understanding (MoU) signed on September 30, 2026, marking a collaboration that promises to transform the landscape of therapeutic candidates in this challenging field.
Understanding the Problem: Fibrotic Diseases
Fibrotic diseases, including cancer-associated fibrosis, pose substantial challenges for medical researchers and clinicians alike. These diseases involve excessive accumulation of connective tissue, leading to organ dysfunction and failure. Accurately measuring changes in fibrotic tissue is crucial in evaluating therapeutic efficacy, yet it has traditionally been a complex and subjective process. HistoIndex's cutting-edge technology offers a solution by providing objective and sensitive measurements that facilitate a more rigorous evaluation of potential therapeutic candidates.
The Power of Collaboration
With ASTAR's extensive scientific expertise and resources paired with HistoIndex's innovative imaging technology, the collaboration aims to make substantial headway in preclinical evaluations of treatments. By harnessing HistoIndex's quantitative tissue analysis capabilities, researchers can track responses more precisely and make informed decisions about advancing candidates through development stages.
Dr. Lisa Ooi, Assistant Chief Executive of ASTAR’s Biomedical Research Council (BMRC), emphasized the importance of rigorous evaluation in the drug development process. She stated, “Understanding whether a therapeutic candidate can prevent, halt or reverse fibrosis requires accurate measurement of changes in fibrotic tissue. This collaboration will provide the necessary framework for such assessments.”
Echoing her sentiments, Dr. Gideon Ho, CEO of HistoIndex, reflected on the personal significance of the partnership, stating, “As one of ASTAR's early medtech spin-offs, we are thrilled to retract our globally validated technology back to Singapore, facilitating advancements in precision medicine and identifying viable therapies for fibrotic diseases.”
A Platform for Knowledge Exchange
The collaboration is not solely restricted to therapeutic evaluations; it also fosters a broader exchange of scientific knowledge between HistoIndex and ASTAR. Opportunities for joint initiatives in biomarker discovery, translational research, and commercialization are anticipated, opening new avenues for innovation in the medical field.
Showcasing Innovations
In addition to this partnership, HistoIndex is set to showcase its digital pathology and AI-driven tissue analysis capabilities at the upcoming AASLD The Liver Meeting® Exhibition in Denver, Colorado. This event will present an opportunity for HistoIndex to demonstrate its invaluable solutions in enhancing the assessment of fibrosis, contributing to drug development efforts.
About HistoIndex
Founded in 2010, HistoIndex specializes in advanced imaging solutions that visualize and quantify fibrosis in biological tissues without the need for staining. By integrating state-of-the-art biophotonic technology with AI-based analysis, the company is driving forward innovative tools that enhance clinical research and drug efficacy evaluation worldwide.
About ASTAR
The Agency for Science, Technology and Research (ASTAR) plays a crucial role as Singapore's lead public sector research agency. It aims to foster innovation through collaboration between public and private sectors, ultimately enhancing societal outcomes in health, urban living, and sustainability. A*STAR's extensive research efforts span various disciplines, contributing significantly to the nation's economic growth and capabilities in science and technology.
This partnership marks a vital step in addressing the complexities surrounding fibrotic diseases, paving the way for new treatments that could vastly improve patient outcomes. As both organizations embark on this journey, the medical community and patients alike eagerly anticipate the hopeful advancements that will emerge.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.